Literature DB >> 12393501

Prognostic value of angiogenesis in solitary bone plasmacytoma.

Shaji Kumar1, Rafael Fonseca, Angela Dispenzieri, Martha Q Lacy, John A Lust, Linda Wellik, Thomas E Witzig, Morie A Gertz, Robert A Kyle, Philip R Greipp, S Vincent Rajkumar.   

Abstract

Angiogenesis plays an important role in the biology of multiple myeloma (MM) and has prognostic importance in this disease. Solitary plasmacytoma is a localized plasma cell malignancy that progresses to MM in a significant number of patients. We examined if angiogenesis is increased in solitary plasmacytoma and if it can help identify patients likely to progress to myeloma. We studied angiogenesis in plasmacytoma biopsy samples and bone marrow biopsies from 25 patients. High-grade angiogenesis was present in 64% of plasmacytomas. In contrast, bone marrow angiogenesis was low in all patients. Patients with high-grade angiogenesis in the plasmacytoma sample were more likely to progress to myeloma and had a shorter progression-free survival compared with patients with low-grade angiogenesis (P =.02). Angiogenesis is increased in solitary plasmacytoma and is a significant predictor of progression to myeloma and provides further evidence of its importance in the pathogenesis of myeloma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393501     DOI: 10.1182/blood-2002-08-2441

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  Myeloma as a model for the process of metastasis: implications for therapy.

Authors:  Irene M Ghobrial
Journal:  Blood       Date:  2012-04-24       Impact factor: 22.113

2.  Solitary Plasmacytoma of Frontal Bone: A Case Report.

Authors:  Aditya Gargava; Sudhakar Vaidya; J K Sharma
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2018-04-13

3.  Immunoglobulin free light chains and solitary plasmacytoma of bone.

Authors:  David Dingli; Robert A Kyle; S Vincent Rajkumar; Grzegorz S Nowakowski; Dirk R Larson; John P Bida; Morie A Gertz; Terry M Therneau; L Joseph Melton; Angela Dispenzieri; Jerry A Katzmann
Journal:  Blood       Date:  2006-06-01       Impact factor: 22.113

Review 4.  Multiple myeloma.

Authors:  S Vincent Rajkumar
Journal:  Curr Probl Cancer       Date:  2009 Jan-Feb       Impact factor: 3.187

5.  Angiogenesis and multiple myeloma.

Authors:  Nicola Giuliani; Paola Storti; Marina Bolzoni; Benedetta Dalla Palma; Sabrina Bonomini
Journal:  Cancer Microenviron       Date:  2011-07-07

6.  Metachronous solitary plasmacytoma.

Authors:  Robin Khosa; Shishir Seth; Sapna Nangia
Journal:  BMJ Case Rep       Date:  2017-10-19

7.  Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways.

Authors:  Marta Segarra; Ester Lozano; Marc Corbera-Bellalta; Carme Vilardell; Maria-Teresa Cibeira; Jordi Esparza; Nora Izco; Joan Bladé; Maria C Cid
Journal:  Haematologica       Date:  2009-10-08       Impact factor: 9.941

Review 8.  Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing.

Authors:  Michele Moschetta; Yawara Kawano; Antonio Sacco; Angelo Belotti; Rossella Ribolla; Marco Chiarini; Viviana Giustini; Diego Bertoli; Alessandra Sottini; Monica Valotti; Claudia Ghidini; Federico Serana; Michele Malagola; Luisa Imberti; Domenico Russo; Alessandro Montanelli; Giuseppe Rossi; Michaela R Reagan; Patricia Maiso; Bruno Paiva; Irene M Ghobrial; Aldo M Roccaro
Journal:  Curr Osteoporos Rep       Date:  2017-10       Impact factor: 5.096

9.  Rapid progression of solitary plasmacytoma to multiple myeloma in lumbar vertebra.

Authors:  Jin Seo Yang; Yong Jun Cho; Suk Hyung Kang; Hyuk Jai Choi
Journal:  J Korean Neurosurg Soc       Date:  2013-11-30

10.  Solitary plasmacytoma of jaw bone: A case report and systematic review of fifty cases from literature.

Authors:  Harshal Suryavanshi; Sangeeta Patankar; Snehal Dhumal; Sheetal Choudhari
Journal:  J Oral Maxillofac Pathol       Date:  2021-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.